Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is that the response rate of soft tissue sarcoma will be
improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that
cabozantinib priming will increase the response to nivolumab and ipilimumab.